Legal Limitations Associated with Microdosing Buprenorphine

References

• Alibrahim, A., Marsh, J. C., Amaro, H., Kong, Y., Khachikian, T., & Guerrero, E. (2022). Disparities in expected driving time to opioid treatment and treatment completion: Findings from an exploratory study. BMC Health Services Research, 22(1), 478. https://doi.org/10.1186/s12913-022-07886-7
   PubMed Web of Science ®Google Scholar
• Andraka-Christou, B. (2021). Addressing racial and ethnic disparities in the use of medications for opioid use disorder. Health Affairs (Project Hope), 40(6), 920–927. https://doi.org/10.1377/hlthaff.2020.02261
   PubMed Web of Science ®Google Scholar
• Andrilla, C. H. A., Jones, K. C., & Patterson, D. G. (2020). Prescribing practices of nurse practitioners and physician assistants waivered to prescribe buprenorphine and the barriers they experience prescribing buprenorphine. The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association, 36(2), 187–195. https://doi.org/10.1111/jrh.12404
   PubMed Web of Science ®Google Scholar
• Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2018). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 0, 1–5. https://doi.org/10.1111/jrh.12307
   Google Scholar
• Antoine, D., Huhn, A. S., Strain, E. C., Turner, G., Jardot, J., Hammond, A. S., & Dunn, K. E. (2021). Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine/naloxone. The American Journal on Addictions, 30(1), 83–87. https://doi.org/10.1111/ajad.13069
   PubMed Web of Science ®Google Scholar
• Becker, W. C., Frank, J. W., & Edens, E. L. (2020). Switching from high-dose, long-term opioids to buprenorphine: A case series. Annals of Internal Medicine, 173(1), 70–71. https://doi.org/10.7326/l19-0725
   PubMed Web of Science ®Google Scholar
• CFR Part 8. (2016). Substance abuse & mental health services administration DoHHS (pp. 44712–44739).
   Google Scholar
• Ciccarone, D. (2019). The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. The International Journal on Drug Policy, 71, 183–188. https://doi.org/10.1016/j.drugpo.2019.01.010
   PubMed Web of Science ®Google Scholar
• De Aquino, J. P., Fairgrieve, C., Klaire, S., & Garcia-Vassallo, G. (2020). Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting. Journal of Addiction Medicine, 14(5), e271–e273. https://doi.org/10.1097/ADM.0000000000000618
   PubMed Web of Science ®Google Scholar
• del Pozo, B., Atkins, D., Andraka-Christou, B., et al. (2023). Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015–2021. Drug and Alcohol Dependence Reports, 6:6doi–6d10. 1016/j.dadr.2023.100131
   Google Scholar
• Dooling, B. C. E., & Stanley, L. E. (2022). A vast and discretionary regime: Federal regulation of methadone as a treatment for opioid use disorder. https://regulatorystudies.columbian.gwu.edu/sites/g/files/zaxdzs4751/files/2022-08/gw-reg-studies_report_federal-methadone-regulations_bdooling-and-lstanley.pdf
   Google Scholar
• Hämmig, R., Kemter, A., Strasser, J., von Bardeleben, U., Gugger, B., Walter, M., Dürsteler, K. M., & Vogel, M. (2016). Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method. Substance Abuse and Rehabilitation, 7, 99–105. https://doi.org/10.2147/sar.S109919
   PubMed Web of Science ®Google Scholar
• Hochstatter, K. R., Terplan, M., Mitchell, S. G., Schwartz, R. P., Dusek, K., Wireman, K., & Gryczynski, J. (2022). Characteristics and correlates of fentanyl preferences among people with opioid use disorder. Drug and Alcohol Dependence, 240, 109630. https://doi.org/10.1016/j.drugalcdep.2022.109630
   PubMed Web of Science ®Google Scholar
• Jenkins, R. A. (2021). The fourth wave of the US opioid epidemic and its implications for the rural US: A federal perspective. Preventive Medicine, 152(Pt 2), 106541. https://doi.org/10.1016/j.ypmed.2021.106541
   PubMedGoogle Scholar
• Klaire, S., Zivanovic, R., Barbic, S. P., Sandhu, R., Mathew, N., & Azar, P. (2019). Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series. The American Journal on Addictions, 28(4), 262–265. https://doi.org/10.1111/ajad.12869
   PubMed Web of Science ®Google Scholar
• Lambdin, B. H., Bluthenthal, R. N., Tookes, H. E., Wenger, L., Morris, T., LaKosky, P., & Kral, A. H. (2022). Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States. Drug and Alcohol Dependence, 237, 109504. https://doi.org/10.1016/j.drugalcdep.2022.109504
   PubMed Web of Science ®Google Scholar
• Lee, D. S., Hann, J. E., Klaire, S. S., Nikoo, M., Negraeff, M. D., & Rezazadeh-Azar, P. (2020). Rapid induction of buprenorphine/naloxone for chronic pain using a microdosing regimen: A case report. A&A Practice, 14(2), 44–47. https://doi.org/10.1213/xaa.0000000000001138
   PubMed Web of Science ®Google Scholar
• Martin, L., Lennox, R., Regenstreif, L., & O’Shea, T. (2019). Case report: “Striving to skip the withdrawal” using buprenorphine–naloxone microdosing for hospitalized patients.
   Google Scholar
• National Institute on Drug Abuse. Fentanyl DrugFacts. https://nida.nih.gov/publications/drugfacts/fentanyl
   Google Scholar
• Office of the Secretary DoHaHS. (2022). 42 CFR Part 8, Notice of Proposed Rulemaking. In: Substance Abuse and Mental Health Services Administration (SAMHSA), Services DoHaH, editors.
   Google Scholar
• Pilarinos, A., Bingham, B., Kwa, Y., et al. (2023). Interest in using buprenorphine-naloxone among a prospective cohort of street-involved young people in Vancouver, Canada. Journal of Substance Use and Addiction Treatment, 148:209005. https://doi.org/10.1016/j.josat.2023.209005
   Google Scholar
• Randhawa, P. A., Brar, R., & Nolan, S. (2020). Buprenorphine-naloxone "microdosing": An alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market. CMAJ: Canadian Medical Association Journal = Journal de L’Association Medicale Canadienne, 192(3), E73. https://doi.org/10.1503/cmaj.74018
   PubMed Web of Science ®Google Scholar
• Rozylo, J., Mitchell, K., Nikoo, M., Durante, S. E., Barbic, S. P., Lin, D., Mathias, S., & Azar, P. (2020). Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Addiction Science & Clinical Practice, 15(1), 2. https://doi.org/10.1186/s13722-020-0177-x
   PubMed Web of Science ®Google Scholar
• Santo, T., Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., Chen, A., Tran, L. T., Bharat, C., Padmanathan, P., Cousins, G., Dupouy, J., Kelty, E., Muga, R., Nosyk, B., Min, J., Pavarin, R., Farrell, M., & Degenhardt, L. (2021). Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis. JAMA Psychiatry, 78(9), 979–993. https://doi.org/10.1001/jamapsychiatry.2021.0976
   PubMed Web of Science ®Google Scholar
• Saxon, A. J., Hser, Y.-I., Woody, G., & Ling, W. (2013). Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. Journal of Food and Drug Analysis, 21(4), S69–S72. https://doi.org/10.1016/j.jfda.2013.09.037
   PubMedGoogle Scholar
• Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., Leslie, D. L., Sorbero, M. J., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015). Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. The Milbank Quarterly, 93(3), 561–583. https://doi.org/10.1111/1468-0009.12137
   PubMed Web of Science ®Google Scholar
• Terasaki, D., Smith, C., & Calcaterra, S. L. (2019). Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(10), 1023–1029. https://doi.org/10.1002/phar.2313
   Google Scholar
• The Consolidated Appropriations Act, 2023 (the Omnibus bill). (2023). Section 1262.
   Google Scholar